Inhibiting inflammation with milk oligosaccharides
A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
1. A method for inhibiting inflammation in a subject, the method comprising administering to a subject in need thereof an effective amount of a composition consisting essentially of one or more human milk-derived oligosaccharides, wherein at least one of the one or more milk-derived oligosaccharides is 2′-fucosyllactose, 3-Fucosyllactose (3-FL), fucopentaose I (LNF-I), or lactodifucotetraose (LDFT); and wherein the subject is a human subject having ulcerative colitis, Crohn's disease, or irritable bowel syndrome.
2. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides are conjugated with a carbohydrate, a lipid, a polypeptide or a peptide to form a glycoconjugate.
3. The method of claim 1 , wherein the composition is formulated for oral administration.
4. The method of claim 3 , wherein the composition further contains a pharmaceutically acceptable carrier and a lubricating agent.
5. The method of claim 4 , wherein the composition further contains a sweetening agent, a flavoring agent, a coloring agent, or a combination thereof.
6. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides are synthesized chemically, isolated from milk, or produced by a microorganism.
7. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides comprise 2′ fucosyllactose, 3-Fucosyllactose (3-FL), fucopentaose I (LNF-I), and lactodifucotetraose (LDFT).
8. The method of claim 7 , wherein the subject is a human subject having irritable bowel syndrome.
9. A method for inhibiting inflammation in a subject, the method comprising administering to a subject in need thereof an effective amount of a composition comprising one or more human milk-derived oligosaccharides, wherein at least one of the one or more milk-derived oligosaccharides is 2′-fucosyllactose, 3-Fucosyllactose (3-FL), fucopentaose I (LNF-I), and lactodifucotetraose (LDFT); wherein the subject is a human subject having ulcerative colitis, Crohn's disease, or irritable bowel syndrome; wherein the composition is not human milk; and wherein the composition is free of other human milk components.
10. The method of claim 9 , wherein the one or more human milk-derived oligosaccharides are the only agent in the composition that inhibits inflammation.
11. The method of claim 9 , wherein the one or more human milk-derived oligosaccharides are conjugated with a carbohydrate, a lipid, a polypeptide or a peptide to form a glycoconjugate.
12. The method of claim 9 , wherein the composition is formulated for oral administration.
13. The method of claim 12 , wherein the composition further contains a pharmaceutically acceptable carrier and a lubricating agent.
14. The method of claim 13 , wherein the composition further contains a sweetening agent, a flavoring agent, a coloring agent, or a combination thereof.
15. The method of claim 9 , wherein the one or more human milk-derived oligosaccharides are synthesized chemically, isolated from milk, or produced by a microorganism.
16. The method of claim 9 , wherein the one or more milk-derived oligosaccharides comprise 2′ fucosyllactose, 3-Fucosyllactose (3-FL), fucopentaose I (LNF-I), and lactodifucotetraose (LDFT).
17. The method of claim 16 , wherein the subject is a human subject having irritable bowel syndrome.